A molecular profile of a patient with hematologic malignancy, for whom standard-of-care had
failed, is identified using next generation sequencing. Patients are assigned to early
clinical trials of targeted agent based on the molecular profiling or physician's choice. The
improvement of outcomes in the intention-to-treat population is investigated.